Royalty Pharma (RPRX)
Buys drug royalties and funds late-stage medicines for future royalty streams.
$58.19
vs last close−0.33 (−0.56%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 536 | 596 | 568 | 537 | 565 | 594 | 568 | 579 | 609 | 622 | 631 | 674 |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 268 |
| Gross profit | 536 | 596 | 568 | 537 | 565 | 594 | 568 | 579 | 609 | 622 | 629 | 406 |
| 385 | −17 | 642 | 268 | −170 | 232 | 34 | 369 | 182 | 234 | −3 | 273 | |
| Research & development | 51 | 1 | 1 | 1 | 1 | 1 | 51 | 301 | 51 | 51 | 40 | 98 |
| 57 | 59 | 58 | 55 | 57 | 68 | 111 | 180 | 119 | 164 | 159 | 162 | |
| General & administrative | 57 | 59 | 58 | 55 | 57 | 68 | 111 | 180 | 119 | 164 | 159 | 162 |
| Other expenses | 277 | −77 | 584 | 212 | −228 | 164 | −127 | −111 | 13 | 19 | −202 | 13 |
| Operating income | 151 | 613 | −74 | 270 | 735 | 362 | 534 | 210 | 427 | 388 | 632 | 133 |
| −29 | 105 | 70 | −75 | 71 | −27 | −101 | −119 | 17 | −32 | −164 | −52 | |
| Interest income | 23 | 7 | 7 | 13 | 18 | 9 | 11 | 8 | 7 | 7 | 6 | 5 |
| Interest expense | 46 | 47 | 44 | 49 | 67 | 66 | 65 | 69 | 80 | 94 | 94 | 94 |
| Other non-operating income | −17 | −152 | −114 | 26 | −138 | −39 | 35 | 50 | −97 | −62 | 71 | −42 |
| Income before tax | 122 | 718 | −4 | 194 | 806 | 334 | 433 | 91 | 444 | 356 | 468 | 81 |
| Net income from continuing operations | 122 | 718 | −4 | 194 | 806 | 334 | 433 | 91 | 444 | 356 | 468 | 81 |
| Net income | 72 | 494 | 5 | 102 | 544 | 208 | 238 | 30 | 288 | 214 | 295 | 18 |
| EPS, basic | $0.21 | $1.48 | $0.01 | $0.23 | $1.22 | $0.47 | $0.55 | $0.09 | $1.05 | $0.64 | $0.68 | $0.04 |
| EPS, diluted | $0.16 | $1.10 | $0.01 | $0.23 | $1.21 | $0.47 | $0.41 | $0.07 | $0.67 | $0.50 | $0.53 | $0.04 |
| Weighted average shares, basic | 448 | 448 | 449 | 451 | 446 | 446 | 435 | 424 | 432 | 432 | 432 | 445 |
| Weighted average shares, diluted | 601 | 602 | 597 | 597 | 593 | 589 | 578 | 562 | 560 | 560 | 560 | 557 |
| EBITDA | 168 | 765 | 40 | 243 | 873 | 400 | 499 | 159 | 525 | 451 | 563 | 176 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| EBIT | 168 | 765 | 40 | 243 | 873 | 400 | 499 | 159 | 524 | 450 | 562 | 175 |